BTOG Guidance & Responses
Member Login
Sign Up For Free

New NICE Result: Lorlatinib

BTOG is disappointed that lorlatinib has not been recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) in adults who have not had an ALK inhibitor (1st line, CROWN indication).

This recommendation is not intended to affect treatment with lorlatinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Click here for full details on the NICE website.

Other News from NICE

New guidance recommends Nivolumab to treat resectable NSCLC

BTOG wishes to inform members of a new NICE release that has been published today for nivolumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer.   NICE has recommended nivolumab...

Lorlatinib update

BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended Lorlatinib as an option for ALK-positive advanced non-small-cell lung cancer in adults who have not had an ALK inhibitor. There is a commercial access agreement for...

Durvalumab update

BTOG wishes to inform members of a new NICE release that has been published today.NICE has recommended Durvalumab, within its marketing authorisation, as an option to treat limited-stage small-cell lung cancer that has not progressed after platinum-based...